Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Treston, Bryony; Geoghegan, Sarah

doi:10.1080/21645515.2024.2341505

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could affect the outcome, resulting in a relatively positive representation of the findings. Another notable difference with previous reports is the high familiarity with RSV, which might reflect increased public awareness and media attention around RSV or selection bias in our cohort 28 . Still, we believe that this survey provides healthcare professionals and policy makers with important information to improve the enrolment of RSV protection in the coming years.…”

Section: Discussioncontrasting

confidence: 88%

“…Maternal vaccination protects the infant directly from birth until at least 6 months of age, with still effective but waning immunity until 1 year of age and the highest gain found in the first months of life when infants are most vulnerable 16 28 29 . Parents have become more familiar with this strategy for infant protection since pertussis vaccination is part of the standard National Immunization Program (NIP) in many countries.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Respiratory syncytial virus (RSV) prevention: perception and willingness of expectant parents in the Netherlands

Harteveld,

van Leeuwen,

Euser

et al. 2024

Preprint

View full text Add to dashboard Cite

ObjectivesTo investigate the perception and willingness of pregnant women and their partners to accept maternal vaccination or neonatal immunization against respiratory syncytial virus (RSV).DesignA cross-sectional survey studySettingPregnant women and their partners were recruited through healthcare professionals (midwives, gynaecologists, and Youth Health care), social media platforms (Instagram, LinkedIn, Facebook via institutions like the Spaarne Hospital), and the 9-Months Fair in the Netherlands.Main outcome measuresWillingness and motivation in decision-making for both maternal RSV vaccination or neonatal RSV immunization among pregnant women and their partners, including strategy preferences, and informational needs.ResultsIn total 1001 pregnant women (mean age: 31.1 years) and their partners (mean age: 33.2 years) completed the survey. On average, they were 24 weeks pregnant at the time, and 54.6% had no other children yet. The majority was Dutch-born (95.2% of women); with 68.3% of women having completed higher education and with overall strong pro-vaccination attitudes (93.9% of partners intended to vaccinate their expected newborn). The overall acceptability to vaccination and immunization was high, with 87% of respondents indicating they would (likely) accept both strategies. A positive attitude towards both methods was associated with previous experience with severity of RSV, intention to vaccinate the newborn and parental vaccination status during childhood and current pregnancy. When the choice was given, the majority of participants, in particular those with children and the intention to breastfeed, favoured maternal vaccination over passive immunization of infants (75.3% of the pregnant and 71.6% of the partners). A majority of the respondents cited optimal protection for the child and knowledge of RSV as important factors for accepting RSV prophylaxis.ConclusionsWhile most participants would accept both strategies for RSV protection of their infant, a majority, especially those with other children, favored maternal vaccination, due to concerns about infant safety and awareness of RSV severity.

show abstract

Section: Discussioncontrasting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Respiratory syncytial virus (RSV) prevention: perception and willingness of expectant parents in the Netherlands

Harteveld,

van Leeuwen,

Euser

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Nirsevimab: Alleviating the burden of RSV morbidity in young children

Loe,

Soenong,

Lee

et al. 2024

J Paediatrics Child Health

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTIs) and hospital admissions in early childhood. Recent advancements in novel preventive therapies, including extended half‐life monoclonal antibodies and antenatal vaccination, have afforded new opportunities to significantly reduce the burden of this infection. Nirsevimab is a novel monoclonal antibody that provides sustained protection against RSV for at least 5 months among newborns and young children. It has received regulatory approval in numerous countries and is being implemented across various settings. Two pivotal Phase 3 trials (MELODY, HARMONIE) demonstrated significant reductions in RSV‐associated LRTI hospitalisations following nirsevimab administration, with treatment efficacy of 62.1% and 83.2%. Emerging real‐world data from early adopters of nirsevimab corroborates these findings. Studies from Spain, Luxembourg, France and the USA report effectiveness rates between 82% and 90% in preventing RSV‐associated hospitalisations among infants entering their first RSV season. Current implementation strategies for nirsevimab have primarily focused on seasonal administration for all infants, aligned to local RSV seasons, and often include catch‐up doses for those born before the season begins. Available cost‐effectiveness analyses indicate that while nirsevimab offers significant potential public health benefits, its adoption must carefully consider economic factors such as treatment costs, implementation strategies tailored to local viral epidemiology, and logistics for vaccine delivery. Overall, nirsevimab presents a promising opportunity to alleviate the burden of severe RSV infections in young children. However, ongoing surveillance and refinements in implementation strategies are crucial to optimise its impact and ensure sustainability across diverse health‐care settings.

show abstract

Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody

Cited by 2 publications

References 29 publications

Respiratory syncytial virus (RSV) prevention: perception and willingness of expectant parents in the Netherlands

Respiratory syncytial virus (RSV) prevention: perception and willingness of expectant parents in the Netherlands

Nirsevimab: Alleviating the burden of RSV morbidity in young children

Contact Info

Product

Resources

About